In a consortium including 23 637 breast cancer patients and 25 579 controls of East Asian ancestry, we investigated 70 single-nucleotide polymorphisms (SNPs) in 67 independent breast cancer susceptibility loci recently identified by genome-wide association studies (GWASs) conducted primarily in European-ancestry populations. SNPs in 31 loci showed an association with breast cancer risk at P < 0.05 in a direction consistent with that reported previously. Twenty-one of them remained statistically significant after adjusting for multiple comparisons with the Bonferroni-corrected significance level of <0.0015. Eight of the 70 SNPs showed a significantly different association with breast cancer risk by estrogen receptor (ER) status at P < 0.05. With the exception of rs2046210 at 6q25.1, the seven other SNPs showed a stronger association with ER-positive than ER-negative cancer. This study replicated all five genetic risk variants initially identified in Asians and provided evidence for associations of breast cancer risk in the East Asian population with nearly half of the genetic risk variants initially reported in GWASs conducted in European descendants. Taken together, these common genetic risk variants explain ∼10% of excess familial risk of breast cancer in Asian populations.
INTRODUCTION
Breast cancer is one of the most common malignancies diagnosed among women worldwide, including East Asian women (1) . Genetic factors play an important role in the etiology of both sporadic and familial breast cancer (2, 3) . Since 2007, common genetic risk variants in approximately 25 loci have been associated with breast cancer risk (3 -18) . However, with only a few exceptions (9, 13, 14, 16, 18) , the vast majority of these risk variants were initially identified in studies conducted in European descendants (4 -8,10-12,15,17) . Several previous studies have evaluated some of these risk variants in relation to breast cancer risk in non-European populations (19 -26) , including East Asian women (19,24 -26) . Sample sizes in these studies, however, were small, and only a few variants were evaluated. Recently, as part of the international Collaborative Oncological Gene-Environment Study (COGS), 42 additional genetic susceptibility loci for breast cancer risk were identified in genome-wide association studies (GWASs) conducted in European descendants (27) .
Given differences in genetic architecture, breast cancer incidence rates and environmental exposures across different ethnic populations, it is important to systematically investigate whether these genetic risk variants are associated with breast cancer risk in other ethnic populations. This investigation not only assesses the generalizability of initial GWAS findings but also provides valuable data to guide fine-mapping efforts in the search for disease variants. In this study, we combined data generated in the Asia Breast Cancer Consortium (ABCC) with Asian samples from COGS to systematically evaluate risk variants in all 67 loci identified to date.
RESULTS
This study combined data obtained from 41 586 women (19 963 cases and 21 623 controls) included in the ABCC and 12 893 women (6269 cases and 6624 controls) included in COGS. All study participants were of Asian ancestry and recruited from studies conducted in Asian countries and the USA (Table 1 and Supplementary Material, Table S1 ). The ABCC consisted of two stages. Stage 1 included two GWASs, in which 5285 Chinese women and 4777 Korean women were scanned using primarily Affymetrix GenomeWide Human SNP Array 6.0 [906 602 single-nucleotide polymorphisms (SNPs)]. After applying quality-control (QC) filters described previously (9, 18, 24) , 5242 Chinese women (2918 cases and 2324 controls; 690 947 SNPs) and 4298 Korean women (2246 cases and 2052 controls; 555 525 SNPs) remained in the GWASs. These data were used to impute autosomal SNPs present in HapMap II release 22 using the MACH program v1.0 (28) . Only SNPs with high imputation quality [R-squared (RSQ) . 0.50] were included in the analysis. To increase statistical power, we genotyped additional samples included in Stage 2 of the ABCC for 44 of the 70 SNPs identified in GWASs (called index SNPs in subsequent text). As part of a large collaboration of GWASs of multiple cancer sites (27) , COGS samples were genotyped on a custom Illumina Infinium BeadChip, which included either index SNPs (n ¼ 67) or SNPs (n ¼ 2) in strong linkage disequilibrium (LD) (r 2 . 0.8), with the index SNPs selected for the data analysis of this study.
Evaluation of SNPs in 26 previously reported loci in Europeans and Asians
One index SNP per locus was selected for most of the previously reported loci, except for 10q21/ZNF365 and 16q12/ TOX3, for which two SNPs were selected per locus as they are not in LD in Asians. For 17 of the 28 SNPs, de novo genotyping was conducted for additional samples (ranging from 3348 to 27 166) included in the ABCC as part of previous studies (Stage 2) (9, 13, 14, 18, 19, 23, 26, 29) . A meta-analysis of ABCC Stages 1 and 2 data was performed under the fixed-effects model (30) , and results are presented in Table 2 (left panel). Detailed stage-specific results are presented in Supplementary Material, Table S2. Table 2 also includes  results obtained from Asian women included in COGS  (middle panel) , as well as combined results generated by a meta-analysis of data from the ABCC and COGS (right panel). Heterogeneity tests for associations of these SNPs Human Molecular Genetics, 2013 Adjusted for age and study site if appropriate. g Data described in studies reported in references (9, 13, 14, 18, 19, 23, 26, 29) were included in this analysis. h Combined results for all available studies after excluding samples that overlapped in both ABCC and COGS. i P-value for heterogeneity between ABCC and COGS results derived using a Cochran's Q-test.
between the ABCC and COGS were statistically significant only for rs10995190/ZNF365 (P ¼ 0.04), for which the minor allele frequency (MAF) is only 0.02 in Asians. Of the 28 SNPs evaluated, 17 showed associations with breast cancer risk at P , 0.05 in Asian women in the same direction as previously reported, and 11 of them remained statistically significant after adjusting for multiple comparisons of 67 SNPs with the Bonferroni-corrected significance level of 0.0015 (0.10/67, one-sided test). However, the effect sizemeasured using per-allele odds ratios (ORs) in Asians-was smaller than that initially identified in Europeans (Fig. 1 ), and the difference was statistically (P , 0.05) or marginally (P , 0.06) significant for six of the replicated SNPs (Supplementary Material, Table S3 ). Five breast cancer-associated signals were previously discovered in Asian GWASs (9, 13, 14, 18) , and all of them were replicated in COGS samples with a combined P-value of 1.95 × 10 262 for rs2046210 (6q25.1/ESR1), 2.83 × 10 232 for rs4784227 (16q12/TOX3), 2.27 × 10 213 for rs9485372 (6q25/TAB2), 2.98 × 10 28 for rs10822013 (10q21/ZNF365) and 6.69 × 10 28 for rs7107217 (11q24/BARX2). In the 10q21/ZNF365 locus, rs10995190, identified initially in a GWAS of European descendants, was not related to breast cancer risk in Asians, whereas the association with rs10822013, identified initially in the ABCC (14) , was replicated in COGS samples with a borderline significant P-value. At 16q12.1/TOX3, associations with both rs4784227 and rs3803662 remained statistically significant after mutual adjustment (Table 3) . Of the 11 SNPs not replicated in our study, 4 have a very low MAF (≤0.05) in Asians, whereas the rest show very weak associations, with allelic ORs ranging from 0.93 to 1.06. The CASP8 SNP (rs1045485) identified previously through a candidate gene study (4) has a very low MAF in Asians and was not replicated in the study (data not shown in the table). Additional analyses were performed to evaluate the association of the 17 replicated SNPs by major study populations included in this study, Chinese, Koreans and Japanese (Supplementary Material, Table S4 ). With the exception of rs889312 (P ¼ 0.002) and rs3817198 (P ¼ 0.012), the remaining 15 SNPs showed a consistent association in Chinese, Koreans and Japanese. SNPs rs889312 and rs3817198 were statistically associated with breast cancer risk only in Koreans and Chinese, respectively. Because of a small sample size, only three SNPs (rs2046210, rs1219648 and rs4784227) were found to be associated with breast cancer in Japanese at P , 0.05.
Evaluation of SNPs in 42 newly identified loci in Europeans
In addition to GWAS data, we genotyped 27 index SNPs in 7294 cases and 9404 controls included in the ABCC. Results for this analysis are presented in Table 4 and Supplementary Material, Table S5 . Of the 42 SNPs evaluated (1 SNP per locus), 16 showed associations with breast cancer risk at P , 0.05 in the same direction reported in European-ancestry populations (27) . Of them, 10 remained statistically significant after adjusting for multiple comparisons (P , 0.0015). Adjusted allelic ORs for the replicated SNPs ranged from 0.92 to 1.16, showing a smaller effect size than those presented in Table 2 . SNP rs11820646 at 11q24 is correlated with rs7217217 (r 2 ¼ 0.386 in Asian and r 2 ¼ 0.842 in CEU) identified initially in the ABCC (18) and replicated in Asian samples included in COGS ( Table 2 ). The association with rs7107217 remained after adjusting for rs11820646 (P ¼ 2.73 × 10 24 ) ( Table 3) . On the other hand, adjusting for rs7107217 diminished the association with rs11820646, suggesting that rs7107217 may tag the disease variant better than rs11820646 in East Asians. Of the 22 non-replicated SNPs, 3 have a small MAF in both Asia and European samples (based on the HapMap data), including rs132390 ( 500 kb downstream to the CHEK2 gene), rs11571833 (BRCA2) and rs11814448 (10p12). The MAF for the other six SNPs (rs1353747, rs720475, rs7072776, rs7904519, rs2588809 and rs13329835) also was very low (,0.05) in Asian samples but not in European samples (mean MAF ¼ 0.23) included in the HapMap project. With the exception of three SNPs (rs11242675, rs17817449 and rs3760982), heterogeneity tests were not statistically significant for SNPs between ABCC and COGS samples. Again, the effect size for most of the SNPs in Asians was smaller than those identified in Europeans (Fig. 1) , and the difference was statistically significant for four SNPs (Supplementary Material, Table S3 ). We also performed subgroup analysis for the 16 replicated SNPs by Chinese, Korean and Japanese (Supplementary Material, Table S4 ). Only four SNPs (rs11242675, rs11780156, rs11199914 and rs4808801) showed some evidence of heterogeneity (P , 0.05) in their associations with breast cancer risk in the three populations. In Japanese, however, only two SNPs showed a statistically significant association (rs7697216 and rs4808801), likely due to a small sample size in this group.
Associations by ER status
Of the 70 SNPs in 67 loci evaluated, SNPs in 8 loci showed a significantly different association with breast cancer risk by ER status at P , 0.05 (Table 5 and Supplementary Material,  Table S6 ). With the exception of rs2046210/6q25, the seven other SNPs showed a stronger association with ER-positive cancer compared with ER-negative cancer. In fact, six of the eight SNPs showed no significant association with ER-negative cancer except rs2046210/6q25 (per allele OR ¼ 1.36, P ¼ 6.04 × 10
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) and rs1219648/FGFR2 (per allele OR ¼ 1.08, P ¼ 0.0055). Details of all evaluated SNPs by ER status are presented in Supplementary Material, Table S6 .
DISCUSSION
By analyzing data from up to 23 637 breast cancer cases and 25 579 controls of Asian ancestry, we identified a significant association at P , 0.05 for 31 of the 67 independent breast cancer association signals reported from previous GWASs conducted mostly in European descendants. The number of SNPs identified in our study with a significant association at P , 0.05 was substantially greater than the 1.68 significant associations expected by chance under a null hypothesis (67 × 0.025 ¼ 1.675). Twenty-one of these associations remained statistically significant after adjusting for multiple comparisons using the Bonferroni-corrected P-value of 0.0015. Our study has substantially boosted the number of genetic risk variants identified to date for East Asian women. Together, these SNPs explain 10% of the excess familial risk for breast cancer among East Asian women (Supplementary Material, Table S7 ).
This study represents the largest, most comprehensive effort made to date to evaluate the generalizability of GWAS findings to any non-European population. With 23 637 cases and 25 579 controls included in the study, the statistical power was very large. For some analyses, however, only about 10 200 cases and 9800 controls were included. Even in this sample size set, we still have 85% power to detect associations with ORs as low as 1.10 for an MAF of 0.10 or above (Supplementary Material, Table S8 ). This study was designed to directly evaluate risk variants identified in previous GWASs, and thus, SNPs showing an association at P , 0.05 in the same direction as previously reported were considered statistically significant. It is possible, however, that some of the significant findings (n ¼ 1.68) could be due to chance because of multiple comparisons. Nevertheless, we also presented findings based on a more stringent significant level with the adjustment for multiple comparisons.
Differences in LD patterns between East Asian-and European-ancestry populations are likely to be the major reason for the lack of replication for some of the index SNPs in our study. The vast majority of non-replicated SNPs showed a substantial difference in the frequency of the effect alleles ( Fig. 1 and Supplementary Material, Table S9 ). Fourteen SNPs which did not replicate had very small MAFs in East Asian women (mean ¼ 0.0176) but much higher MAFs in European descendants (mean ¼ 0.177) (P , 0.001) (Supplementary Material, Table S9 ). Most SNPs with an association identified by GWASs are tagging SNPs of the disease variant(s). Because of the differences in LD patterns between East Asian and European populations, some of the SNPs identified by GWASs may be more closely associated with disease variants in European-ancestry populations compared with East Asian populations, which may partially explain the weaker association for some index SNPs in East Asians than European-ancestry populations. Thus, fine-mapping of these regions in both Asian and European populations may be fruitful in identifying relevant disease variants.
Our findings for SNPs located at 10q21/ZNF365 illustrate how differences in LD patterns may result in a different SNP being identified by a GWAS. One SNP at 10q21/ ZNF365 (rs10822013, OR ¼ 1.10, P ¼ 5.87 × 10 29 ) was reported previously to be associated with breast cancer risk in a GWAS conducted in East Asians (14) . This SNP is 26.7 kb upstream of rs10995190, which was identified independently in a GWAS conducted in European descendants (12) . Interestingly, rs10995190, a common SNP in European descendants (MAF ¼ 0.13), is rare in East Asians (MAF ¼ 0.02). It is likely that the disease variants are tagged by different SNPs in East Asians (rs10822013) and Europeans (rs10995190) in this region. SNPs at 16q12.1/TOX3 also are of interest. The two top breast cancer-associated SNPs in this region identified to date are rs4784227 and rs3803662. These two SNPs, however, are highly correlated in Europeans (r 2 ¼ 0.813) but virtually not correlated in Asians (r 2 ¼ 0.139). Although rs4784227 showed a stronger association with breast cancer risk than rs3803662 in Asians, the association with rs3803662 remained statistically significant after adjustment for rs4784227, suggesting the existence of a second disease variant in this region (18) . In vitro experiments have provided evidence for functional significance of rs4784227 (30) . The differences in LD patterns across ethnic groups may help to narrow the region of interest and/or the number of candidate SNPs for fine-mapping analyses to identify disease variants.
The lack of association with index SNPs in some loci could also be explained by allelic heterogeneity, in which different underlying disease variants exist in Asian-and European-ancestry populations, or by possible differences between these populations in genetic and environmental modifiers. In addition to differences in LD patterns between East Asian and European populations, and possible allelic heterogeneity in these populations, other factors may have contributed to weaker associations observed in Asians than in European-ancestry populations for some of the index SNPs. Some SNPs were imputed in the ABCC data set, and thus imputation accuracy may affect the risk estimate. However, we included in the analysis only SNPs that were imputed with high quality (RSQ . 0.5, mean RSQ ¼ 0.92). Furthermore, all SNPs were directly genotyped in the COGS data set, which should facilitate direct comparison of the results obtained in the Asian and European-ancestry samples included in the COGS project. Additional studies, including fine-mapping and functional characterization of SNPs, are needed to clarify the reasons for the different associations observed between Asian-and European-ancestry populations.
In conclusion, our study replicated all five breast cancer risk variants identified previously in GWASs conducted in East Asians and found that nearly half of the variants identified initially in European-ancestry GWASs can be directly replicated in East Asians. These results show the complexity of uniformly applying GWAS findings across ancestral groups. Common genetic variants identified to date explain 14% of familial relative risk (FRR) of breast cancer in European-ancestry populations (27) but only 10% in East Asians. The lower estimated FRR in Asian-than in European-ancestry populations is expected since most known common genetic variants for breast cancer were identified in GWASs conducted in European-ancestry populations, and most of these risk variants show a stronger association with breast cancer risk in European-than in Asian-ancestry populations. It is possible that other risk variants may exist in some of the loci that could show a stronger association with breast cancer risk in Asians than the variants analyzed in this study. It is also possible that multiple independent risk variants may exist in some of the loci we evaluated. Fine-mapping of known breast cancer susceptibility loci may identify breast cancer risk variants more relevant in Asians than those identified initially in GWASs of European-ancestry populations, which could improve risk assessment in Asians. 
MATERIALS AND METHODS
All methodology, results and interpretation in this study were reported according to the STREGA guidelines (31) and STROBE statement (32) . Approval was granted from the relevant institutional review boards at all study sites, and all included participants gave informed consent.
Study populations
This study is a collaborative effort between the ABCC and the international COGS. The ABCC included 19 963 cases and 21 623 controls from 16 studies ( Table 1 ). Detailed descriptions of these participating studies and demographic characteristics of study participants have been published previously (9, 13, 14, 18 
Genotyping methods
The ABCC consisted of two GWASs, in which 5285 Chinese women and 4777 Korean women were scanned primarily using Affymetrix Genome-Wide Human SNP Array 6.0 (Stage 1). Genotyping protocols for Stage I have been described elsewhere (9, 24) . In the Chinese GWASs, the initial 300 samples were genotyped using the Affymetrix GeneChip Mapping 500K Array Set. ; or (iv) poor cluster plot in either cases or controls. After these QC exclusions, the final data set included 2246 cases and 2052 controls for 555 525 markers.
Genotyping for Stage 2 in the ABCC was completed primarily using a custom Illumina Infinium BeadChip and the iPLEX Sequenom MassArray platform. To compare consistency between Stage-1 (Affymetrix) and Stage-2 genotyping, we included 43 and 45 Stage-1 samples in the assay using the Illumina BeadChip and Sequenom platforms, respectively, which yielded concordance rates of 99.9 and 99.5%, respectively, compared with results obtained from the Affymetrix 6.0 genotyping. Additional QC samples were used in the Sequenom assay, including one negative control (water), two blinded duplicates and two samples from the HapMap project in each 96-well plate. The mean concordance rate was 99.7% for the blind duplicates and 98.9% for HapMap samples. Some samples were genotyped using TaqMan assays, for which assay protocols were developed and validated at the Vanderbilt Molecular Epidemiology Laboratory, and assay reagents were provided to investigators who performed the assays. For the MEC study, SNP data needed for the study were extracted from the data generated using Illumina Human 660W.
Genotyping in COGS was conducted using a custom Illumina Infinium BeadChip, which included 211 155 SNPs, as part of a large collaboration for replication of promising associations selected from GWASs of multiple cancers (27) . Individuals were excluded for any of the following reasons: genotypically not female XX; overall call rate ,95%; low or high heterozygosity (P , 10
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); individuals not concordant with previous genotyping with BCAC; individuals where genotypes for the duplicate sample appeared to be from a different individual; or 'cryptic' duplicates where phenotypic data indicated that the individuals were different. For known and cryptic duplicates, the sample with the lower call rate was excluded. We attempted to identify first-degree relative pairs using identity-by-state estimates based on approximately 37 000 uncorrelated SNPs. For apparent first-degree relative pairs, we removed the control from a case-control pair, otherwise we removed the individual with the lower call rate. Ethnic outliers were identified by multidimensional scaling, combining COGS data with the three HapMap2 populations, based on a subset of 37 000 uncorrelated markers which passed QC (including approximately 1000 selected as ancestry informative markers). Individuals with .15% minority ancestry, based on the first two components, were excluded. Although the vast majority of study participants were of East-Asian origin, women from other Asian regions also were included in studies from Singapore (SGBCC) (92 Indians and 180 Malays) and Malaysia (MyBrCa) (152 Indians and 166 Malays). Exclusion of these subjects should not change the results given the small sample size. Therefore, for these studies, no exclusions for ethnic outliers were made, but principal components analysis adequately corrected for inflation. Principal components analyses were carried out based on a subset of 37 000 uncorrelated SNPs, and two principal components were used for the studies in Asian populations. We excluded SNPs which had a call rate ,95%, deviated from HWE in controls at P , 10
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, or had genotype discrepancies in .2% of duplicate samples, across all COGS consortia. Final analyses were based on 199 961 SNPs.
Statistical analyses
PLINK version 1.07 (http://pngu.mgh.harvard.edu/~purcell/p link/) was used to analyze genome-wide data obtained in Stage 1 (44) . A set of 4305 SNPs with MAF ≥ 35% and a distance ≥100 kb between two adjacent SNPs were selected to evaluate the population structure in the Chinese GWASs. Inflation factor l was estimated to be 1.04. Similar analyses were performed for the Korean GWASs, which yielded a l of 1.04 (24) . Inflation factor l is ,1.03 in all eight studies included in COGS. These data suggest that any population substructure, if present, should not have any appreciable effect on the results. ORs associated with each SNP and 95% CIs were estimated using logistic regression implemented in Plink with adjustment for age.
We used the program MACH 1.0 (28) to impute genotypes for autosomal SNPs which were present in HapMap Phase II release 22 for samples included in the Chinese and Korean GWASs. Only SNPs with imputation quality score RSQ . 0.50 were included in analyses. Dosage data for imputed SNPs for samples in each Stage-1 study were analyzed using the program mach2dat (28) . Associations between genotype dosage and breast cancer risk were assessed assuming a log-additive model. ORs associated with each SNP and 95% confidence intervals (CIs) were estimated using logistic regression adjusted for age.
Individual data were obtained from each study included in the ABCC and COGS for two separate pooled analyses. Results from these two pooled analyses were combined in meta-analyses performed under a fixed-effects model using the METAL program (45) . Data quality for each study was evaluated by examining genotyping cluster plots and HWE in controls for all SNPs. SNPs which failed to meet data QC criteria were excluded from the analysis. Case -control differences for selected demographic characteristics and major risk factors were evaluated using t-tests (for continuous variables) or x 2 tests (for categorical variables). Associations between SNPs and breast cancer risk were assessed using ORs and 95% CIs derived from logistic regression models. ORs were estimated for the effect allele based on a log-additive model and adjusted for age and study site, when appropriate. Stratified analyses by ER status were performed.
The fraction of the FRR explained by a single locus, under a multiplicative model, can be expressed as ln(l)/ln(l o ), where l is the FRR to offspring of an affected individual due to the locus, and l o is the overall FRR. l o is assumed to be 1.8 for breast cancer (46) . Note that if an individual locus fits a log-additive model, the formula of l for a single locus is:
where p is the frequency of the risk allele, q ¼ 1 2 p is the frequency of the reference allele and r is the per-allele relative risk. We assumed that the risks associated with each locus combine multiplicatively, and the FRRs also multiply, so that the combined contribution is using formula: ln (P i l i )/ln(l O ).
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